142 related articles for article (PubMed ID: 27580058)
1. Pharmacokinetics and Safety of Valganciclovir in Pediatric Heart Transplant Recipients 4 Months of Age and Younger.
Bradley D; Moreira S; Subramoney V; Chin C; Ives J; Wang K;
Pediatr Infect Dis J; 2016 Dec; 35(12):1324-1328. PubMed ID: 27580058
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
[TBL] [Abstract][Full Text] [Related]
3. Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients.
Padullés A; Colom H; Bestard O; Melilli E; Sabé N; Rigo R; Niubó J; Torras J; Lladó L; Manito N; Caldés A; Cruzado JM; Grinyó JM; Lloberas N
Antimicrob Agents Chemother; 2016 Apr; 60(4):1992-2002. PubMed ID: 26824942
[TBL] [Abstract][Full Text] [Related]
4. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients.
Chamberlain CE; Penzak SR; Alfaro RM; Wesley R; Daniels CE; Hale D; Kirk AD; Mannon RB
Am J Transplant; 2008 Jun; 8(6):1297-302. PubMed ID: 18444933
[TBL] [Abstract][Full Text] [Related]
6. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics and Bayesian Estimation of the Area Under the Concentration-Time Curve for Ganciclovir in Adult Chinese Renal Allograft Recipients After Valganciclovir Administration.
Chen B; Hu SS; Rui WB; An HM; Zhai XH; Wang XH; Lu JQ; Shao K; Zhou PJ
J Clin Pharmacol; 2021 Mar; 61(3):328-338. PubMed ID: 32926418
[TBL] [Abstract][Full Text] [Related]
8. Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients.
Rui WB; An HM; Shao K; Zhai XH; Lu JQ; Hu SS; Chen B; Zhou PJ
Eur J Clin Pharmacol; 2019 May; 75(5):677-686. PubMed ID: 30643927
[TBL] [Abstract][Full Text] [Related]
9. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients.
Vaudry W; Ettenger R; Jara P; Varela-Fascinetto G; Bouw MR; Ives J; Walker R;
Am J Transplant; 2009 Mar; 9(3):636-43. PubMed ID: 19260840
[TBL] [Abstract][Full Text] [Related]
10. Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children.
Jorga K; Chavanne C; Frey N; Lave T; Lukacova V; Parrott N; Peck R; Reigner B
Clin Pharmacol Ther; 2016 Dec; 100(6):761-769. PubMed ID: 27530217
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients.
Franck B; Woillard JB; Théorêt Y; Bittencourt H; Demers E; Briand A; Marquet P; Lapeyraque AL; Ovetchkine P; Autmizguine J
Br J Clin Pharmacol; 2021 Aug; 87(8):3105-3114. PubMed ID: 33373493
[TBL] [Abstract][Full Text] [Related]
12. Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure.
Lefeuvre S; Chevalier P; Charpentier C; Zekkour R; Havard L; Benammar M; Amrein C; Boussaud V; Lillo-Le Louët A; Guillemain R; Billaud EM
Transpl Infect Dis; 2010 Jun; 12(3):213-9. PubMed ID: 20102551
[TBL] [Abstract][Full Text] [Related]
13. Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients.
Franck B; Autmizguine J; Åsberg A; Théorêt Y; Marquet P; Ovetchkine P; Woillard JB
Clin Pharmacokinet; 2021 Nov; 60(11):1449-1462. PubMed ID: 34050910
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
Park JM; Lake KD; Arenas JD; Fontana RJ
Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
[TBL] [Abstract][Full Text] [Related]
15. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.
Pescovitz MD; Pruett TL; Gonwa T; Brook B; McGory R; Wicker K; Griffy K; Robinson CA; Jung D
Transplantation; 1998 Oct; 66(8):1104-7. PubMed ID: 9808499
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
[TBL] [Abstract][Full Text] [Related]
17. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
18. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
[TBL] [Abstract][Full Text] [Related]
19. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
[TBL] [Abstract][Full Text] [Related]
20. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
Brady RL; Green K; Frei C; Maxwell P
Transpl Infect Dis; 2009 Apr; 11(2):106-11. PubMed ID: 19054381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]